Cargando…
Cancer Testis Antigens and Immunotherapy: Where Do We Stand in the Targeting of PRAME?
PRAME or PReferentially expressed Antigen in Melanoma is a testis-selective cancer testis antigen (CTA) with restricted expression in somatic tissues and re-expression in various cancers. It is one of the most widely studied CTAs and has been associated with the outcome and risk of metastasis. Altho...
Autores principales: | , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6678383/ https://www.ncbi.nlm.nih.gov/pubmed/31311081 http://dx.doi.org/10.3390/cancers11070984 |
_version_ | 1783441088003964928 |
---|---|
author | Al-Khadairi, Ghaneya Decock, Julie |
author_facet | Al-Khadairi, Ghaneya Decock, Julie |
author_sort | Al-Khadairi, Ghaneya |
collection | PubMed |
description | PRAME or PReferentially expressed Antigen in Melanoma is a testis-selective cancer testis antigen (CTA) with restricted expression in somatic tissues and re-expression in various cancers. It is one of the most widely studied CTAs and has been associated with the outcome and risk of metastasis. Although little is known about its pathophysiological function, PRAME has gained interest as a candidate target for immunotherapy. This review provides an update on our knowledge on PRAME expression and function in healthy and malignant cells and the current immunotherapeutic strategies targeting PRAME with their specific challenges and opportunities. We also highlight some of the features that position PRAME as a unique cancer testis antigen to target. |
format | Online Article Text |
id | pubmed-6678383 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-66783832019-08-19 Cancer Testis Antigens and Immunotherapy: Where Do We Stand in the Targeting of PRAME? Al-Khadairi, Ghaneya Decock, Julie Cancers (Basel) Review PRAME or PReferentially expressed Antigen in Melanoma is a testis-selective cancer testis antigen (CTA) with restricted expression in somatic tissues and re-expression in various cancers. It is one of the most widely studied CTAs and has been associated with the outcome and risk of metastasis. Although little is known about its pathophysiological function, PRAME has gained interest as a candidate target for immunotherapy. This review provides an update on our knowledge on PRAME expression and function in healthy and malignant cells and the current immunotherapeutic strategies targeting PRAME with their specific challenges and opportunities. We also highlight some of the features that position PRAME as a unique cancer testis antigen to target. MDPI 2019-07-15 /pmc/articles/PMC6678383/ /pubmed/31311081 http://dx.doi.org/10.3390/cancers11070984 Text en © 2019 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Review Al-Khadairi, Ghaneya Decock, Julie Cancer Testis Antigens and Immunotherapy: Where Do We Stand in the Targeting of PRAME? |
title | Cancer Testis Antigens and Immunotherapy: Where Do We Stand in the Targeting of PRAME? |
title_full | Cancer Testis Antigens and Immunotherapy: Where Do We Stand in the Targeting of PRAME? |
title_fullStr | Cancer Testis Antigens and Immunotherapy: Where Do We Stand in the Targeting of PRAME? |
title_full_unstemmed | Cancer Testis Antigens and Immunotherapy: Where Do We Stand in the Targeting of PRAME? |
title_short | Cancer Testis Antigens and Immunotherapy: Where Do We Stand in the Targeting of PRAME? |
title_sort | cancer testis antigens and immunotherapy: where do we stand in the targeting of prame? |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6678383/ https://www.ncbi.nlm.nih.gov/pubmed/31311081 http://dx.doi.org/10.3390/cancers11070984 |
work_keys_str_mv | AT alkhadairighaneya cancertestisantigensandimmunotherapywheredowestandinthetargetingofprame AT decockjulie cancertestisantigensandimmunotherapywheredowestandinthetargetingofprame |